Πέμπτη 4 Φεβρουαρίου 2021

Benefit and danger from immunotherapy in myasthenia gravis

xloma.fota13 shared this article with you from Inoreader

Abstract

In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου